Literature DB >> 1899817

Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension.

J M Morgan1, M Griffiths, R M du Bois, T W Evans.   

Abstract

Reduction of pulmonary vascular resistance by a high inspired oxygen concentration is a common, but not universal phenomenon in patients with pulmonary vascular disease of varying etiology that may determine their response to long-term domiciliary oxygen therapy. We therefore determined changes in PVR during oxygen therapy in two patient populations not previously studied: systemic sclerosis (n = 8, mean age +/- SEM, 44.5 +/- 5.4 years) and primary pulmonary hypertension (n = 7, mean age +/- SEM 38 +/- 7.8 years). All patients were hypoxemic (arterial oxygen tension, on air 9.5 +/- 1.2 kPa for SSc and 8.3 +/- 0.6 kPa for PPH, p greater than 0.05). Right atrial pressure, pulmonary artery pressure, pulmonary artery occlusion pressure, systemic arterial pressure, PaO2 and cardiac output by thermodilution were measured at three, 20-min intervals while inspiring air and again after inspiring 60 percent oxygen for 30 min. The PVR fell significantly with oxygen in patients with SSc from 797.6 +/- 179.2 to 610 +/- 151.6 dynes/s/cm-5 (p less than 0.01), and this fall correlated with baseline PAP and PaO2 prior to oxygen therapy (r = 0.86, p less than 0.025; r = 0.77, p less than 0.05, respectively). In patients with PPH, there was no significant fall in PVR with oxygen (from 969 +/- 80.2 to 851.9 +/- 91.2 dynes/s/cm-5, p greater than 0.05) and no predictor of a vasodilator response in individual patients. In SSc, hypoxic pulmonary vasoconstriction contributes more consistently to elevated PVR than in patients with PPH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899817     DOI: 10.1378/chest.99.3.551

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

3.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

Review 4.  Primary pulmonary hypertension. Practical therapeutic recommendations.

Authors:  L J Rubin
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 5.  Pulmonary hypertension: work in progress.

Authors:  Paul D Boyce; Aaron B Waxman
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

6.  Comparison of Pulmonary Artery Pressure Measurement With Doppler Echocardiography or With Right Heart Catheterization in Patients With Congenital Heart Disease.

Authors:  Dan Yin; Ying Wang; Min Zheng; Huijing Wei; Mi Li; Tiewei Lv; Yonghong Bai; Jie Tian; Xiaoyun Wu
Journal:  Front Pediatr       Date:  2019-10-18       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.